Core Viewpoint - The stock of Giant Bio (02367) has declined nearly 4%, currently trading at HKD 36.82, with a transaction volume of HKD 241 million, following a report from CMB International that downgraded revenue growth forecasts for 2025/26 due to short-term pressures on Comfy [1] Group 1: Sales Performance - During the "Double Eleven" shopping festival, the company's sales were under pressure, primarily due to disappointing performance from the Comfy brand, which saw sales drop by 20% on Tmall and 50% on Douyin [1] - In contrast, the Collgene brand achieved positive growth during the same period, indicating a divergence in brand performance [1] Group 2: Strategic Adjustments - The company is actively adjusting its channel strategy in response to competitive pressures within the industry, while maintaining strategic focus to protect pricing and consumer experience [1] - Management has increased the proportion of self-broadcast channels, laying a foundation for long-term growth despite current challenges [1] Group 3: Financial Guidance - Management has lowered the earnings guidance for the current year, expecting revenue to be flat or slightly down year-on-year, and has revised profit forecasts to reflect a mid to high single-digit decline [1]

Group 1 - The stock of Giant Bio (02367.HK) has experienced a decline of nearly 4%, currently down 3.86% at HKD 36.82 [1] - The trading volume for Giant Bio reached HKD 241 million [1]

Core Viewpoint - The stock of Giant Bio (02367) has declined nearly 4%, with a current price of HKD 36.82 and a trading volume of HKD 241 million, following a report from CMB International that downgraded revenue growth forecasts for 2025/26 due to short-term pressures on Comfy brand sales [1] Group 1: Company Performance - CMB International has revised the revenue growth forecast for Giant Bio to -3.5% and 13.6% for 2025/26, indicating a challenging sales environment during the "Double Eleven" shopping festival, primarily due to underperformance in the sales of the Comfy brand [1] - Management has adjusted the performance guidance for the year, expecting revenue to remain flat or slightly decline, and has lowered the net profit forecast to a mid-to-high single-digit percentage decline [1] Group 2: Sales Performance - During the "Double Eleven" period, sales of the Comfy brand on Tmall and Douyin saw a year-on-year decline of 20% and 50%, respectively, while the Collgene brand achieved positive growth during the same period [1] - The company is actively adjusting its channel strategy in response to competitive pressures in the industry, while maintaining strategic focus to enhance pricing and consumer experience, and increasing the proportion of self-broadcast channels to lay the foundation for long-term growth [1]

来源：华泰睿思 近期人民币汇率加速升值是国内经济金融数据中的一抹亮色。我们认为汇率升值对出口企业股价造成压力的"常识"并不受数据支持，反而适度升值在本轮 资本流动浪潮、人民币实际有效汇率较低和中外通胀差的存在下有利于企业表现。10月以来市场偏弱的资金面因素主因南向而非外资，港股情绪指标分 项、人民币汇率和EPFR数据均可得到交叉验证。目前我们构建的情绪指标仍在悲观区间摆动，重申港股处在布局区，短期建议关注流动性拐点和此前调 整较多且负面压力逐渐出清的科技和医药，左侧关注大众消费品的α机会，中期（二季度左右）依然维持成长与顺周期的均衡配置观点。 核心观点 汇率升值中出口企业股价承压的"常识"或并非"事实" 我们进一步剥离行业属性来聚焦海外收入差异，发现即便同一行业中，海外收入占比不同企业的表现与汇率走势也无显著相关关系。我们选取了2024年报 中国上市公司中海外收入占比最高的前10大细分行业（包括服饰鞋帽零售、电子、计算机、家电等）共400余样本，按海外收入占比高低将同行业内公司 分成等数量两组样本，并以市值加权形成两个指数。自2015年以来，高海外收入指数跑赢低海外收入指数229%，高低海外收入指数的相对表现 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [4][5]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance, with the Shenwan Beauty Care Index declining by 2.0% from November 28 to December 5, 2025, underperforming the market [4][5]. - Douyin's performance in November met expectations, with domestic brands preparing actively for the upcoming Double 12 sales event, indicating a strong competitive landscape for domestic products [4][10]. - The report highlights the leading market share of Minoxidil products, particularly from Mandi International, which has established itself as a top brand in the hair growth sector [11][12]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 2.2%, while the Shenwan Personal Care Index also dropped by 2.0%, both underperforming against the Shenwan A Index [4][5]. - The top-performing stocks in the sector included Juzhibio (+5.9%) and Hongmian Co. (+3.5%), while the worst performers were Kelao Co. (-7.6%) and Baiya Co. (-4.8%) [6]. Key Market Developments - Mandi International has dominated the Minoxidil market, achieving a revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, with a CAGR of 21.7% [12][13]. - The company has maintained a leading position in the market for ten consecutive years, with a market share of about 57% in the hair loss treatment sector and 71% in the Minoxidil product market as of 2024 [12][14]. E-commerce Insights - In November 2025, Douyin's domestic brand GMV showed significant growth, with brands like Han Shu and New Page experiencing double-digit increases [15][18]. - The overall retail sales of cosmetics in October 2025 grew by 9.6%, driven by the Double 11 shopping festival, indicating a robust recovery in consumer spending [18][20]. Company Announcements - Lin Qingxuan updated its IPO prospectus for the Hong Kong market, reporting a revenue of 1.052 billion yuan in the first half of 2025, a year-on-year increase of 98.3% [22][19]. - The company plans to expand its research and development team and explore international markets in Southeast Asia [22][19]. Market Trends - The Chinese consumer healthcare market is projected to grow from 9.313 billion yuan in 2018 to 16.420 billion yuan in 2024, with a CAGR of 9.9% [13]. - The report emphasizes the increasing market share of domestic brands in the skincare sector, with a notable rise in the competitive landscape against international brands [24].

Investment Rating - The report indicates a positive investment outlook for the wool industry, particularly focusing on leading wool enterprises due to expected price increases and inventory replenishment [1][11]. Core Insights - The wool trend is upward, with a focus on investment opportunities in leading wool companies. After a period of low demand and destocking from 2024 to the first half of 2025, the industry is expected to see a cyclical turning point in the second half of 2025. Downstream demand is gradually recovering, as evidenced by a 42% year-on-year increase in contract liabilities for New Australia Holdings in Q3 2025, and a 12.6% year-on-year decrease in raw material inventory across the industry. This supply-demand dynamic supports a strengthening of wool prices, with the spot price of Australian 19-micron wool rising by 20.44% year-on-year in September 2025 [1][12][13]. - Natural堂 Group has submitted a listing application to the Hong Kong Stock Exchange. As China's third-largest domestic cosmetics group, its main brand, Natural堂, remains a leader among domestic brands. The company focuses on mass-market skincare products, with 68.8% of revenue coming from online channels and a broad offline network. In the first half of 2025, the company's revenue grew by 6.4% year-on-year, aligning with the growth rate of the mass-market skincare industry [1][14][24]. Industry Data Tracking - In October, clothing retail sales began to recover, showing a year-on-year growth of 6.3%, attributed to seasonal promotions and improved consumer traffic due to reduced extreme weather conditions. Jewelry retail also continued to recover, with a year-on-year increase of 9.6% [2][27]. - The cosmetics sector saw a year-on-year retail increase of 9.6% in October, with a significant acceleration in growth compared to September [2][39]. Investment Recommendations - For the apparel sector, Hai Lan Home is recommended for its innovative transformation and strong profitability potential. Li Ning is undergoing operational adjustments, with a potential turning point expected in 2025. In the beauty sector, recommendations include Giant Biological, which has shown resilience, and Jinbo Biological, a leader in collagen products expected to launch new products in the second half of the year. In the gold and jewelry sector, the report recommends Laopu Gold due to its strong brand power amid rising gold prices [3][43].

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - The report highlights the rapid growth of high-end skincare products in China, with a projected compound annual growth rate (CAGR) of 13.8% from 2024 to 2029 [28] - Lin Qingxuan, a high-end domestic skincare brand, is positioned to capitalize on this growth, having updated its IPO prospectus, indicating a potential acceleration in its capital process [25][28] - The report emphasizes the importance of emotional consumption themes and recommends focusing on high-quality companies in high-growth sectors [6][32] Summary by Sections Retail Market Overview - The retail industry index closed at 2310.07 points, down 0.83%, underperforming the Shanghai Composite Index, which rose by 0.37% [5][14] - Among the retail sub-sectors, the professional chain segment saw the largest increase, while the jewelry sector led the year-to-date performance with a 20.56% rise [17][20] Company Focus: Lin Qingxuan - Lin Qingxuan achieved a revenue of 1.05 billion yuan in H1 2025, representing a year-on-year increase of 98.3%, with a net profit of 180 million yuan, up 109.9% [25][28] - The brand's core product, camellia oil, has dominated the facial oil sales market for 11 consecutive years, establishing a strong market presence [25][28] - Lin Qingxuan's online and offline revenue contributions were 65.4% and 34.6%, respectively, with a total of 554 stores, the highest among domestic and international high-end skincare brands [25][28] Investment Themes - Investment Theme 1: Focus on high-end jewelry brands with differentiated product offerings, recommending companies like Chow Tai Fook and Lao Pu Gold [6][32] - Investment Theme 2: Emphasize offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [6][32] - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety ingredient innovations, recommending brands like Maogeping and Proya [6][32] - Investment Theme 4: Target differentiated medical beauty product manufacturers and expanding chain medical beauty institutions, recommending Aimeike and Kedi-B [6][32] Company Performance Highlights - Chow Tai Fook reported a revenue of 38.986 billion HKD in FY2026H1, a slight decline of 1.1%, but a net profit increase of 0.1% [39][40] - Chao Hong Ji achieved a revenue of 6.237 billion yuan in Q1-Q3 2025, up 28.4%, with a net profit increase of 0.3% [42] - The report notes that companies like Proya and Marubi have shown strong performance in the beauty sector, with Proya's revenue reaching 7.098 billion yuan in Q3 2025, up 1.9% [34][35]

Core Insights - The Chinese medical aesthetics industry has surpassed 300 billion yuan, with the light medical aesthetics market expected to grow at a compound annual growth rate (CAGR) of over 20% in the next five years, becoming the mainstream segment by 2024 [1] - Injection projects, as the core growth engine of light medical aesthetics, have seen their market size grow from 25.7 billion yuan in 2018 to 67 billion yuan in 2023, with a CAGR of 21.1%, projected to reach 147 billion yuan by 2027 [1] - The industry faces challenges such as rapid market changes driven by consumer preferences and increasing competition, necessitating innovation in material research to build competitive barriers [1] Market Dynamics - In 2024, the market share of injection materials is projected to be approximately 36% for hyaluronic acid, 29% for botulinum toxin, 19% for collagen, and 16% for regenerative materials [3] - The competition in the hyaluronic acid market has intensified, leading to revenue declines for major companies like Huaxi Biological and Aimeike, with revenue drops of 18.36% and 21.49% respectively in the first three quarters of 2025 [3][4] - In contrast, the recombinant collagen market is rapidly growing, with a projected CAGR of 44.93%, expected to reach 58.57 billion yuan by 2025 [3] Innovation and Product Development - Companies are accelerating new product launches to capture market opportunities, with Huaxi Biological introducing compliant products for facial skin improvement and other companies like Jinbo Biological launching innovative recombinant collagen products [5] - The emergence of new materials such as alginate and hydroxyapatite is set to enrich the market supply, with several products receiving regulatory approval in 2025 [6] Regulatory Environment - The industry is experiencing a shift towards compliance, with increased regulatory scrutiny leading to a "survival of the fittest" scenario, pushing medical aesthetic institutions to accelerate compliance transformations [2] - Despite the growth in compliant products, issues such as illegal operations and counterfeit products remain prevalent, posing risks to consumer safety [11][12] Pricing and Market Structure - The supply expansion has led to a restructuring of interests within the industry, with upstream manufacturers and downstream medical institutions engaged in pricing power struggles [8][9] - New platforms like Xinyang are disrupting traditional pricing models by significantly reducing costs through digitalization and centralized procurement, indicating a shift from a seller's market to a buyer's market [9][10] Future Trends - The industry is expected to evolve towards a more transparent and competitive landscape, with a focus on product and scenario-driven strategies, comprehensive treatment solutions, and enhanced consumer awareness [10] - The ongoing regulatory efforts and market dynamics suggest that the medical aesthetics industry is moving towards a more mature and compliant operational model, emphasizing innovation and safety [14]

Core Insights - The WISE 2025 Business King Conference aims to anchor the future of Chinese business amidst uncertainty, emphasizing the theme "The Scenery Here is Unique" [1] - The conference is characterized by an immersive experience rather than a traditional industry summit, focusing on trends in technology and business practices [1] Group 1: Technology and Consumption Dynamics - Yang Yi, founder of Jinyu Capital, highlighted the positive cycle of "technology empowering consumption and consumption driving technology" as a key force for China's development [2][5] - Jinyu Capital focuses on investing in technology innovation and improving quality of life, aligning with China's 14th Five-Year Plan [6][7] Group 2: Technological Foundations - China has the largest pool of R&D personnel globally, with 28% of high-level tech talent and 37% of STEM graduates [8] - The country is increasing its R&D investment, projected to reach 3.6 trillion yuan in 2024, accounting for 20% of global R&D spending [9] - China leads in manufacturing output, holding 30% of global manufacturing value, and has made significant breakthroughs in key technologies [9][10] Group 3: Consumer Market Potential - China is the world's largest consumer market, with significant growth in disposable income, which reached 41,000 yuan in 2024, a 46-fold increase since 1990 [12] - The country is expected to surpass the U.S. as the largest consumer market by 2025, with retail sales projected to exceed 50 trillion yuan [13] Group 4: Investment Strategies - Jinyu Capital emphasizes the synergy between technology and consumption, viewing them as coexisting elements that drive each other [14] - The firm has identified opportunities in sectors where technology enhances consumer experiences, such as consumer electronics, retail, health, and food industries [15][16] Group 5: Future Opportunities - The integration of AI in both hardware and software is seen as a significant opportunity for entrepreneurs and investors, with AI expected to reshape consumer experiences and productivity [23][24] - The development of consumer-grade AI hardware and software is anticipated to create new product categories and enhance existing ones, driving market growth [25]

Key Points - The top three stocks with net inflows from southbound funds are Meituan-W (03690) with 592 million, Yingfu Fund (02800) with 450 million, and Xiaomi Group-W (01810) with 383 million [1][2] - The top three stocks with net outflows are Tencent Holdings (00700) with -383 million, Zijin Mining (02899) with -284 million, and Hua Hong Semiconductor (01347) with -138 million [1][2] - In terms of net inflow ratio, the top three are Wisdom Hong Kong 100 (02825) at 100.00%, Southern East-West Select (03441) at 87.01%, and Qingdao Bank (03866) at 67.97% [1][3] - The top three stocks with the highest net outflow ratios are Anhui Wanshan Expressway (00995) at -76.47%, Winner Fashion (03709) at -74.17%, and Beijing Capital International Airport (00694) at -59.27% [1][4] Net Inflow Rankings - Meituan-W (03690) had a net inflow of 592 million, representing a 7.56% increase in its closing price to 96.500 [2] - Yingfu Fund (02800) saw a net inflow of 450 million, with a closing price of 26.240, reflecting a slight increase of 0.15% [2] - Xiaomi Group-W (01810) experienced a net inflow of 383 million, closing at 40.700, up by 0.99% [2] Net Outflow Rankings - Tencent Holdings (00700) had a net outflow of -383 million, with a closing price of 617.000, down by 0.40% [2] - Zijin Mining (02899) recorded a net outflow of -284 million, closing at 32.720, up by 1.24% [2] - Hua Hong Semiconductor (01347) faced a net outflow of -138 million, with a closing price of 72.800, down by 2.80% [2] Net Inflow Ratio Rankings - Wisdom Hong Kong 100 (02825) achieved a net inflow ratio of 100.00%, with a net inflow of 6.136 million and a closing price of 30.500, up by 0.93% [3] - Southern East-West Select (03441) had a net inflow ratio of 87.01%, with a net inflow of 9.8862 million and a closing price of 10.450, up by 0.19% [3][4] - Qingdao Bank (03866) recorded a net inflow ratio of 67.97%, with a net inflow of 9.4613 million and a closing price of 4.010, down by 1.23% [4]